
New Jersey Hospitals Say $7.8B in Community Benefits — What That Number Really Counts
The trade group's headline figure is real, but most of it is unpaid patient care. Here is how to read the report without taking the headline at face value.

The trade group's headline figure is real, but most of it is unpaid patient care. Here is how to read the report without taking the headline at face value.

Each clinical trial phase answers one question before a drug moves ahead, and most candidates never finish the climb. The FDA's own numbers show where testing stalls.

An FDA advisory committee meeting ends in advice, not a decision. The people in the room, the scripted process, and what the vote actually means.

A Chilean berry with unusual anthocyanin levels is drawing research attention. Most of the evidence so far comes from lab dishes and mice, not people.

The bodybuilding supplement has a wider case than bigger muscles — here is what the evidence and one longtime skeptic found.

A short, evidence-first list for readers tired of shelf clutter — and honest notes on what the science does not support.